← All Globestar Therapeutics CORP filings

Globestar Therapeutics CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
GSTC
Globestar Therapeutics CORP
10-Q: GlobeStar Therapeutics Reports Q3 2024 Results, Shifts Business Focus Away From Multiple Sclerosis Treatments
GlobeStar Therapeutics reports a net loss for Q3 2024 and announces a shift in business focus away from Multiple Sclerosis treatments.
OTC.Pink
GSTC
Globestar Therapeutics CORP
10-Q: GlobeStar Therapeutics Reports Q2 2024 Results with Ongoing Losses and Focus on Financing
GlobeStar Therapeutics Corporation reported a net loss of $338,721 for the six months ended March 31, 2024, and is actively seeking additional financing to continue operations.
OTC.Pink
GSTC
Globestar Therapeutics CORP
10-Q: GlobeStar Therapeutics Reports Q1 2024 Results: No Revenue, Continued Losses, and Going Concern Uncertainty
GlobeStar Therapeutics Corporation reports no revenue and a net loss of $163,759 for the quarter ended December 31, 2023, with substantial doubt about its ability to continue as a going concern.